Paclitaxel (taxol) is a very powerful tool for the oncologist, having a very active role in primary management of ovarian cancer and others (e.g. breast cancer). However, a peripheral neuropathy occurs and can be debilitating in patients who have to receive high cumulative dosage. In a recent study conducted at Columbia University (New York), the administration of oral glutamine, as a short course after taxol administration, reduced the severity of the peripheral neuropathy. This clearly needs to further studied in larger trials but may be important.